Jae‐Hoon Kim

ORCID: 0000-0001-6599-7065
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ovarian cancer diagnosis and treatment
  • Cancer, Lipids, and Metabolism
  • Endometrial and Cervical Cancer Treatments
  • Cervical Cancer and HPV Research
  • PARP inhibition in cancer therapy
  • Metabolomics and Mass Spectrometry Studies
  • Uterine Myomas and Treatments
  • Cancer-related molecular mechanisms research
  • RNA modifications and cancer
  • Endometriosis Research and Treatment
  • Reproductive System and Pregnancy
  • Intraperitoneal and Appendiceal Malignancies
  • Molecular Biology Techniques and Applications
  • Epigenetics and DNA Methylation
  • Cancer Genomics and Diagnostics
  • Cancer Mechanisms and Therapy
  • Ferroptosis and cancer prognosis
  • Cancer-related Molecular Pathways
  • MicroRNA in disease regulation
  • BRCA gene mutations in cancer
  • Cancer Cells and Metastasis
  • Sarcoma Diagnosis and Treatment
  • Cancer, Hypoxia, and Metabolism
  • Lung Cancer Research Studies
  • Minimally Invasive Surgical Techniques

Yonsei University
2016-2025

Gangnam Severance Hospital
2016-2025

Seoul St. Mary's Hospital
1996-2024

Daejeon St. Mary's Hospital
2021-2024

Catholic University of Korea
2004-2024

Korea Food Research Institute
2024

Sejong University
2023-2024

Korea Atomic Energy Research Institute
2024

Maria Fertility Hospital
2024

Korea Research Institute of Bioscience and Biotechnology
2001-2023

Éric Pujade-Lauraine Jonathan A. Ledermann Frédèric Selle Val Gebski Richard T. Penson and 95 more Amit M. Oza Jacob Korach Tomasz Huzarski Andrés Poveda Sandro Pignata Michael Friedlander Nicoletta Colombo Philipp Harter Keiichi Fujiwara Isabelle Ray‐Coquard Susana Banerjee Joyce F. Liu Elizabeth Lowe Ralph Bloomfield Patricia Pautier Jacob Korach Tomasz Huzarski Tomasz Byrski Patricia Pautier Michael Friedlander Philipp Harter Nicoletta Colombo Sandro Pignata Giovanni Scambia Maria Ornella Nicoletto Fiona Nussey Andrew R. Clamp Richard T. Penson Amit M. Oza A. Poveda Velasco Manuel Rodrigues Jean‐Pierre Lotz Frédèric Selle Isabelle Ray‐Coquard Diane Provencher Aleix Prat Aparicio Laura Vidal Boixader Clare L. Scott Kenji Tamura Mayu Yunokawa Alla Lisyanskaya Jacques Médioni Nicolas Pécuchet Coraline Dubot Thibault De La Motte Rouge Marie‐Christine Kaminsky B. Weber Alain Lortholary Christine Parkinson Jonathan A. Ledermann Sarah Williams Susana Banerjee Jonathan A. Cosin James Hoffman Richard T. Penson Marie Plante Allan Covens Gabe S. Sonke Florence Joly Anne Floquet Susana Banerjee Holger W. Hirte Amnon Amit Tjoung-Won Park-Simon Koji Matsumoto Sergei Tjulandin Jae‐Hoon Kim Laurence Gladieff Roberto Sabbatini David M. O’Malley Patrick Timmins Daniel Kredentser Nuria Laínez Milagro M.P. Barretina Ginesta Ariadna Tibau Martorell Alfonso Gómez De Liaño Lista Belén Ojeda González Linda Mileshkin Masaki Mandai Ingrid Boere Petronella B. Ottevanger Joo‐Hyun Nam Elias Abdo Filho Salima Hamizi Francesco Cognetti David Warshal Elizabeth Dickson-Michelson Scott Kamelle Nathalie D. McKenzie Gustavo C. Rodriguez Deborah K. Armstrong Eva Chalas Paul Celano Kian Behbakht Susan A. Davidson

10.1016/s1470-2045(17)30469-2 article EN publisher-specific-oa The Lancet Oncology 2017-07-26

Although microRNAs have recently been recognized as riboregulators of gene expression, little is known about microRNA expression profiles in serous ovarian carcinoma. We assessed the and association between prognosis carcinoma.Twenty patients diagnosed with carcinoma eight treated for benign uterine disease December 2000 September 2003 were enrolled this study. The examined using DNA microarray Northern blot analyses.Several differentially expressed compared normal tissues, including miR-21,...

10.1158/1078-0432.ccr-07-1731 article EN Clinical Cancer Research 2008-05-01

Development of new biomarkers for ovarian cancer is needed early detection and disease monitoring. Analyses involving complementary DNA (cDNA) microarray data can be used to identify up-regulated genes in cells, whose products may then further validated as potential biomarkers.To describe validation studies an gene known osteopontin, previously identified using a cDNA system.Experimental cross-sectional were conducted healthy human surface epithelial cell lines cultures, archival...

10.1001/jama.287.13.1671 article EN JAMA 2002-04-03
Andrés Poveda Anne Floquet Jonathan A. Ledermann Rebecca Asher Richard T. Penson and 95 more Amit M. Oza Jacob Korach Tomasz Huzarski Sandro Pignata Michael Friedlander Alessandra Baldoni Tjoung-Won Park-Simon Kenji Tamura Gabe S. Sonke Alla Lisyanskaya Jae‐Hoon Kim Elias Abdo Filho Tsveta Milenkova Elizabeth Lowe Philip Rowe Ignace Vergote Éric Pujade-Lauraine Jacob Korach Tomasz Huzarski Tomasz Byrski Patricia Pautier Michael Friedlander Philipp Harter Nicoletta Colombo Sandro Pignata Giovanni Scambia Maria Ornella Nicoletto Fiona Nussey Andrew R. Clamp Richard T. Penson Amit M. Oza A. Poveda Velasco Manuel Rodrigues Jean‐Pierre Lotz Frédèric Selle Isabelle Ray‐Coquard Diane Provencher Aleix Prat Aparicio Laura Vidal Boixader Clare L. Scott Kenji Tamura Mayu Yunokawa Alla Lisyanskaya Jacques Médioni Nicolas Pécuchet Coraline Dubot Thibault De La Motte Rouge Marie‐Christine Kaminsky B. Weber Alain Lortholary Christine Parkinson Jonathan A. Ledermann Sarah Williams Susana Banerjee Jonathan A. Cosin James Hoffman Richard T. Penson Marie Plante Allan Covens Gabe S. Sonke Florence Joly Anne Floquet Susana Banerjee Holger W. Hirte Amnon Amit Tjoung-Won Park-Simon Koji Matsumoto Sergei Tjulandin Jae‐Hoon Kim Laurence Gladieff Roberto Sabbatini David M. O’Malley Patrick Timmins Daniel Kredentser Nuria Laínez Milagro M.P. Barretina Ginesta Ariadna Tibau Martorell Alfonso Gómez De Liaño Lista Belén Ojeda González Linda Mileshkin Masaki Mandai Ingrid Boere Petronella B. Ottevanger Joo‐Hyun Nam Elias Abdo Filho Salima Hamizi Francesco Cognetti David Warshal Elizabeth Dickson-Michelson Scott Kamelle Nathalie D. McKenzie Gustavo C. Rodriguez Deborah K. Armstrong Eva Chalas Paul Celano

10.1016/s1470-2045(21)00073-5 article EN publisher-specific-oa The Lancet Oncology 2021-03-20

Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived (PDGFR) -α/-β, and c-Kit. Preclinical clinical studies support VEGFR PDGFR as targets for advanced ovarian cancer treatment. This study evaluated the role pazopanib maintenance therapy in patients with whose disease did not progress during first-line chemotherapy.Nine hundred forty histologically confirmed ovary, fallopian tube, or peritoneum, International Federation...

10.1200/jco.2014.55.7348 article EN Journal of Clinical Oncology 2014-09-16

Commensal bacteria are critically involved in the establishment of tolerance against inflammatory challenges, molecular mechanisms which just being uncovered. All kingdoms life produce aminoacyl-tRNA synthetases (ARSs). Thus far, non-translational roles ARSs have largely been reported eukaryotes. Here, we report that threonyl-tRNA synthetase (AmTARS) gut-associated bacterium Akkermansia muciniphila is secreted and functions to monitor modulate immune homeostasis. Secreted AmTARS triggers M2...

10.1016/j.chom.2023.05.007 article EN cc-by Cell Host & Microbe 2023-06-01

Adaptation of tumor cells to the host is a major cause cancer progression, failure therapy, and ultimately death. Immune selection drives this adaptation in human by enriching with stem cell-like (CSC-like) phenotype that makes them resistant CTL-mediated apoptosis; however, mechanisms mediate CSC maintenance proliferation are largely unknown. Here, we report immune evolution toward CSC-like arises through Akt signaling pathway via transcriptional induction Tcl1a Nanog. Furthermore, found...

10.1172/jci64057 article EN Journal of Clinical Investigation 2012-10-24

Abstract The activity of the phosphatase and tensin homologue (PTEN) is known to be suppressed via post-translational modification. However, mechanism physiological significance by which modifications lead PTEN suppression remain unclear. Here we demonstrate that destabilization induced EGFR- or oncogenic PI3K mutation-mediated AKT activation in cervical cancer. EGFR/PI3K/AKT-mediated ubiquitination degradation are dependent on MKRN1 E3 ligase. These processes require stabilization...

10.1038/ncomms8769 article EN cc-by Nature Communications 2015-07-17

6002 Background: SOLO2 (ENGOT ov-21; NCT01874353) showed that maintenance therapy with the PARP inhibitor olaparib in pts platinum-sensitive relapsed ovarian cancer (PSROC) and a BRCA mutation (BRCAm) led to statistically significant improvement median progression-free survival (PFS) of 13.6 months vs placebo (hazard ratio [HR] 0.30). Time second progression or death significantly improved (Pujade-Lauraine et al Lancet Oncol 2017) quality-adjusted PFS benefit was seen (Friedlander 2018)...

10.1200/jco.2020.38.15_suppl.6002 article EN Journal of Clinical Oncology 2020-05-20

Cancer stem cell markers have become a major research focus because of their relationship with radiation or chemotherapy resistance in cancer therapy. including OCT4 and SOX2 been found various solid tumors. Here, we investigate the expression clinical significance cervical cancer. To define expression, performed immunohistochemistry for on 305 normal epithelium samples, 289 intraepithelial neoplasia 161 cases compared data clinicopathologic factors, survival rates patients was higher than...

10.1186/s12885-015-2015-1 article EN cc-by BMC Cancer 2015-12-01

The gut microbiota is associated with diverse age-related disorders. Several rejuvenation methods, such as probiotic administration and faecal transplantation, have been applied to alter the microbiome promote healthy ageing. Nevertheless, prolongation of health span aged mice by remodelling remains challenging.Here, we report changes in microbial communities their functions mouse models during ageing three procedures including co-housing, serum-injection parabiosis. Our results showed that...

10.1186/s40168-021-01189-5 article EN cc-by Microbiome 2021-12-15

Abstract Cancer immunotherapy has emerged as a promising cancer treatment. However, the presence of immune-refractory tumor cells limits its clinical success by blocking amplification anti-tumor immunity. Previously, we found that immune selection drives evolution tumors toward multi-modal resistant and stem-like phenotypes via transcription induction AKT co-activator TCL1A NANOG. Here, report crucial role HSP90A at crossroads between NANOG-TCL1A axis multi-aggressive properties...

10.1038/s41467-019-14259-y article EN cc-by Nature Communications 2020-01-28

Abstract Purpose: Early results from the phase II MEDIOLA study (NCT02734004) in germline BRCA1- and/or BRCA2-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) showed promising efficacy and safety with olaparib plus durvalumab. We report of durvalumab an expansion cohort women gBRCAm PSROC (gBRCAm doublet cohort) two cohorts non-gBRCAm PSROC, one which also received bevacizumab (non-gBRCAm triplet cohorts). Patients Methods: In this open-label, multicenter study, PARP...

10.1158/1078-0432.ccr-23-2249 article EN cc-by-nc-nd Clinical Cancer Research 2023-11-08

Abstract Cisplatin resistance along with chemotherapy-induced neuropathic pain is an important cause of treatment failure for many cancer types and represents unmet clinical need. Therefore, future studies should provide evidence regarding the mechanisms potential targets that can overcome as well alleviate pain. Here, we show emergence cisplatin highly associated EGFR hyperactivation, hyperactivation arisen by a transcriptional increase in pain-generating channel, TRPV1, via NANOG....

10.1038/s41467-023-38318-7 article EN cc-by Nature Communications 2023-05-10

The credible constraint of morally hazardous or opportunistic behavior can enhance efficiency. This idea is applied to an examination local government institutions identify how council‐manager constrains opportunism in economic development by substituting low‐power bureaucratic incentives for high‐power electoral incentives. A panel design isolates changes the use strategies instruments 516 cities. central argument presented here that Progressive ideology separation politics and...

10.1111/1540-6210.00324 article EN Public Administration Review 2003-08-14

A seven-year-old male elk (Cervus elaphus nelsoni) was euthanized and necropsied after having a 3-week history of body weight loss, emaciation, excessive salivation, teeth grinding, fever, anorexia, respiratory distress. The imported into Korea from Canada on March 9, 1997. Gross pathologic findings were restricted to diffuse fibrinous pneumonia. Microscopic lesions included mild neuronal vacuolation spongiform change in the neuropil selected brain stem nuclei generalized astrocytosis....

10.1292/jvms.64.855 article EN cc-by-nc-nd Journal of Veterinary Medical Science 2002-01-01

To determine whether osteopontin (OPN) is increased in patients with AS and to investigate its relationship inflammatory disease activity bone remodelling process.This cross-sectional study included 30 23 age- sex-matched healthy controls. We assessed clinical characteristics laboratory parameters including the ESR, CRP, lipid profiles, Bath index (BASDAI) radiographic (BASRI). evaluate metabolism, we tested ALP, OCN C-telopeptide of type I collagen (CTX-I). Plasma levels OPN, TNF-alpha IL-6...

10.1093/rheumatology/ken385 article EN Lara D. Veeken 2008-10-14

Cyclin dependent kinase 1 (Cdk1) have previously reported correlation with cancer growth and a key regulator for cell cycle. Mostly, Cdk1's function of nucleus cycle is well known to be associated cancer, but cytoplasmic traits are not clearly identified, yet. We revealed that tissue microarray blocks epithelial ovarian (n = 249) showed increased level Cdk1 (p < 0.001), in 0.192) histologic type independently. On survival analysis, overexpression conferred significantly worse prognosis...

10.18632/oncotarget.10373 article EN Oncotarget 2016-07-01

Illumina microarray was used to identify differentially expressed genes in three epithelial ovarian cancer (EOC) cells. To validate the data, mRNA and protein level of glucose transporter-1 (GLUT-1) examined. GLUT-1 had an EOC/normal cells ratio 5.51 based on microarray. Real-time PCR immunohistochemistry demonstrated that expression significantly increased EOC (p = .029 p < .001, respectively). On survival analysis, overexpression (HR 4.80, .027) lymph node metastases 8.35, .016) conferred...

10.3109/07357907.2013.849722 article EN Cancer Investigation 2013-10-28
Coming Soon ...